Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Language English Country Great Britain, England Media electronic
Document type Congress
PubMed
30857522
PubMed Central
PMC6410488
DOI
10.1186/s12933-019-0822-4
PII: 10.1186/s12933-019-0822-4
Knihovny.cz E-resources
- Keywords
- CARMELINA, CVOT, Cardiovascular risk, DECLARE-TIMI 58, Diabetes, Harmony Outcomes, ODYSSEY OUTCOMES,
- MeSH
- Biomedical Research methods standards MeSH
- Diabetes Mellitus diagnosis drug therapy epidemiology MeSH
- Endocrinology methods standards MeSH
- Hypoglycemic Agents adverse effects therapeutic use MeSH
- Cardiology methods standards MeSH
- Cardiovascular Diseases diagnosis epidemiology therapy MeSH
- Clinical Trials as Topic methods standards MeSH
- Cooperative Behavior MeSH
- Humans MeSH
- Interdisciplinary Communication MeSH
- Practice Guidelines as Topic MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Congress MeSH
- Names of Substances
- Hypoglycemic Agents MeSH
The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25-26 October 2018. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CARMELINA, DECLARE-TIMI 58 and Harmony Outcomes. Trial implications for diabetes management and the impact of the new ADA/EASD consensus statement treatment algorithm were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for adjunct therapy of type 1 diabetes and, on the occasion of the 10 year anniversary of the FDA's "Guidance for Industry: "should CVOTs be continued and/or modified?" The 5th Cardiovascular Outcome Trial Summit will be held in Munich on 24-25 October 2019 ( http://www.cvot.org ).
Clalit Health Services and Technion Faculty of Medicine 3 Zivoni Street Haifa Israel
Forschergruppe Diabetes e 5 Ingolstaedter Landstraße 1 Neuherberg 85764 Munich Germany
Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain
See more in PubMed
ADA 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(1):S86–S104. PubMed
Sharma A, et al. Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial. Diabetes Care. 2017;40(12):1763–1770. doi: 10.2337/dc17-1091. PubMed DOI
Barnett KN, et al. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with type 2 diabetes in Tayside, Scotland. Diabet Med. 2010;27(10):1124–1129. doi: 10.1111/j.1464-5491.2010.03075.x. PubMed DOI
Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621. doi: 10.2337/dc15-0099. PubMed DOI
Turnbull FM, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298. doi: 10.1007/s00125-009-1470-0. PubMed DOI
Meinert CL, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:789–830. PubMed
Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743. PubMed DOI PMC
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. doi: 10.1001/jama.294.20.joc50147. PubMed DOI
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. doi: 10.1056/NEJMoa072761. PubMed DOI
FDA Background Document. Endocrinologic and metabolic drugs advisory committee meeting. 24/25 October 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM623913.pdf. Accessed 16 Jan 2019.
Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, FDA, Editor. 2008.
Cefalu WT, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2018;41(1):14–31. doi: 10.2337/dci17-0057. PubMed DOI PMC
Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684. PubMed DOI
Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-X. PubMed DOI
Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352. PubMed DOI
Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225. PubMed DOI
Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC
Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. PubMed DOI
Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917. PubMed DOI PMC
Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI
Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI
Marso SP, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. doi: 10.1056/NEJMoa1615692. PubMed DOI PMC
Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328. doi: 10.1056/NEJMoa1203858. PubMed DOI
Schnell O, et al. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016;15(1):139. doi: 10.1186/s12933-016-0456-8. PubMed DOI PMC
Schnell O, et al. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16(1):128. doi: 10.1186/s12933-017-0610-y. PubMed DOI PMC
Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2018. [Epub ahead of print]. PubMed PMC
Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X. PubMed DOI
Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389. PubMed DOI
Schwartz GG, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174. PubMed DOI
Schnell O, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30. doi: 10.1186/s12933-018-0667-2. PubMed DOI PMC
Schnell O, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed DOI PMC
Schnell O, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33. doi: 10.1186/s12933-016-0357-x. PubMed DOI PMC
Rosenstock J, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17:39. doi: 10.1186/s12933-018-0682-3. PubMed DOI PMC
Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664. PubMed DOI
Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–113. doi: 10.1016/S2213-8587(14)70219-0. PubMed DOI PMC
McMurray JJV, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077. PubMed DOI
Seferovic JP, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–340. doi: 10.1016/S2213-8587(17)30087-6. PubMed DOI PMC
Velazquez EJ, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2018;380(6):539–548. doi: 10.1056/NEJMoa1812851. PubMed DOI
Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033. PubMed DOI PMC
de Ferranti SD, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843–2863. doi: 10.2337/dc14-1720. PubMed DOI PMC
Fox LA, et al. Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia. 2018;61(7):1538–1547. doi: 10.1007/s00125-018-4610-6. PubMed DOI PMC
Musen G, et al. Cognitive function deficits associated with long-duration type 1 diabetes and vascular complications. Diabetes Care. 2018;41(8):1749–1756. doi: 10.2337/dc17-1955. PubMed DOI PMC
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653. doi: 10.1056/NEJMoa052187. PubMed DOI PMC
Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care. 2016;39(Supplement 2):S205–S209. doi: 10.2337/dcS15-3014. PubMed DOI
Standl E, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018;41(3):596–603. doi: 10.2337/dc17-1778. PubMed DOI
Warnes H, et al. Metabolic control in type 1 diabetes: is adjunctive therapy the way forward? Diabetes Ther. 2018;9(5):1831–1851. doi: 10.1007/s13300-018-0496-z. PubMed DOI PMC
Mathieu C, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–1710. doi: 10.2337/dc16-0691. PubMed DOI
Pieber TR, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) Diabetes Obes Metab. 2015;17(10):928–935. doi: 10.1111/dom.12494. PubMed DOI PMC
Perkins BA, et al. Sodium–glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–1483. doi: 10.2337/dc13-2338. PubMed DOI
Tamez HE, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78. doi: 10.1186/s40200-015-0210-x. PubMed DOI PMC
Dandona P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552–2559. doi: 10.2337/dc18-1087. PubMed DOI
Henry RR, et al. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265. doi: 10.2337/dc15-1730. PubMed DOI
Sands AT, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181–1188. doi: 10.2337/dc14-2806. PubMed DOI PMC
Garg SK, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–2348. doi: 10.1056/NEJMoa1708337. PubMed DOI
Phend C. FDA advisors: tweak, don’t dump CV outcomes trials. 2018. https://www.medpagetoday.com/cardiology/prevention/75938. Accessed 06 Dec 2018.
Standl E, et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5(5):391–402. doi: 10.1016/S2213-8587(17)30033-5. PubMed DOI
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
